Horizon Therapeutics PLC (HZNP): Price and Financial Metrics

Horizon Therapeutics PLC (HZNP): $116.30

0.05 (+0.04%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add HZNP to Watchlist
Sign Up

HZNP Price/Volume Stats

Current price $116.30 52-week high $116.38
Prev. close $116.25 52-week low $60.03
Day low $116.26 Volume 28,881,200
Day high $116.38 Avg. volume 2,498,525
50-day MA $109.80 Dividend yield N/A
200-day MA $108.24 Market Cap 26.63B

HZNP Stock Price Chart Interactive Chart >


Horizon Therapeutics PLC (HZNP) Company Bio


Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (Source:Wikipedia)


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Rule 17(e) Announcement - Horizon Therapeutics plc

DUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Yahoo | October 6, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL

Yahoo | October 3, 2023

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023.

Yahoo | October 2, 2023

New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes

DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.

Yahoo | September 29, 2023

Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry

DUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing.

Yahoo | September 26, 2023

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 5.17%
3-year 22.90%
5-year 350.43%
YTD N/A
2023 0.00%
2022 5.61%
2021 47.31%
2020 102.07%
2019 85.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!